Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Hodgkin Disease 48Recurrence 13Lymphoma 12Lymphoma, T-Cell, Cutaneous 10Lymphoma, T-Cell, Peripheral 9Mycosis Fungoides 8Lymphoma, T-Cell 7Lymphoma, Large-Cell, Anaplastic 7Sezary Syndrome 5Lymphoma, Non-Hodgkin 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Immunoblastic Lymphadenopathy 4Enteropathy-Associated T-Cell Lymphoma 4Neoplasms, Germ Cell and Embryonal 3Lymphomatoid Papulosis 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Leukemia 3Testicular Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphatic Diseases 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Large Granular Lymphocytic 2Hematologic Neoplasms 2Carcinoma, Embryonal 2

Interventions

pembrolizumab 2Vorinostat 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2Bortezomib 2prednylidene 1pirarubicin 1etoposide phosphate 1Salvia hispanica seed extract 1Methotrexate 1Ifosfamide 1Everolimus 1Etoposide 1Cholecalciferol 1Brentuximab Vedotin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Subcutaneous panniculitis-like T-cell lymphoma × Brentuximab Vedotin × Clear all
NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Northwestern University

Phase 2 Withdrawn
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡